Search Results
Your search for ,HOW matches 8288 pages
Showing 2101 - 2150Molecular Tumor Profiling May Improve Treatment Matching for Patients With Metastatic Breast Cancer
The use of multigene sequencing and SNP array as a therapeutic decision tool improved the outcomes of patients with metastatic breast cancer if the patients carried alterations classified in the I/II tiers of the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT), according to...
I-SPY2 Study Finds Tumor Biology Is a More Significant Factor Than Race in Predicting Response to Breast Cancer Treatment
Data analysis from the I-SPY2 clinical trial found that among women with high-risk breast cancer, race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response (pCR) and event-free survival. The study, which is being presented by...
Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment
Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline ...
Yuki Muroyama, MD, PhD, on A Novel Marker of Clinical Response to PD-1 Blockade Under Study
Yuki Muroyama, MD, PhD, of the University of Pennsylvania Perelman School of Medicine, discusses the interaction between the immune system and a novel marker—T-cell DNA damage and repair response—to understand how that interaction may affect immune cell biology and therapeutic response (Abstract...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Can Antihistamines Influence Response to Immunotherapy?
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines was associated with improved responses to immune checkpoint inhibitors. The preclinical study, published by Li et al in Cancer Cell, demonstrated that the histamine receptor H1 (HRH1) acts...
Research Assesses Molecular Hallmarks of Moles and Melanomas
Moles and melanomas both originate from the same type of cell—melanocytes. A study published by McNeal et al in eLife Magazine aimed to explain how common moles and melanomas form and why moles can subsequently change into melanoma. Melanocytes are cells that give color to the skin to protect it...
American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award
The American Cancer Society (ACS) and Flatiron Health recently presented the 2021 Real-World Data Impact Awards, which will support research into health disparities among patients with advanced pancreatic and breast cancers. This year marks the third year of the joint grant-making program, under...
The Role of Spirituality in Palliative Care
National surveys consistently show that spirituality and religion are important components in the lives of most Americans, with more than 90% of adults expressing a belief in God and more than 70% identifying religion as one of the most important influences in their lives.1 Studies also show that...
Mortality Risk in Patients With Cancer and SARS–CoV-2 Higher Among Older Patients With B-Cell Malignancies and Those Who Previously or Currently Smoke
A recent study published in JCO Oncology Practice found that patients with certain cancers have a higher mortality risk than those with other cancer types if they have contracted the novel coronavirus (SARS–CoV-2).1 Specifically, older patients with B-cell malignancies who acquire SARS–CoV-2 who...
COVID-19 Resources for People With Cancer
ASCO has compiled a number of resources to help people with cancer navigate COVID-19. Coronavirus and COVID-19: What People With Cancer Need to Know Cases of COVID-19 have arisen all over the world. Here’s what people with cancer and cancer survivors need to know about the disease. Available at...
Duration of Endocrine Therapy in Breast Cancer: How Much of a Good Thing Is Too Much?
Estrogen receptor–positive breast cancer is the most common type of breast cancer, diagnosed in more than 2.3 million women around the world each year, including more than 200,000 in the United States alone. Adjuvant endocrine therapy is a mainstay of treatment for these millions of women and is a...
Achieving Equity in Cancer Care for Adolescents and Young Adults With Cancer
Although cancer in adolescents and young adults (AYAs), defined by the National Cancer Institute as those between the ages of 15 and 39, is relatively rare—in 2020 nearly 90,000 AYAs were diagnosed with cancer and about 9,300 died of the disease1—and 5-year relative survival rates are high, between ...
Adjuvant Immunotherapy: The Next Chapter in Advancements in Renal Cell Carcinoma
Renal cell carcinoma is a common malignancy among men and women in the United States.1 The incidence continues to increase with the ever-increasing use of contemporary medical imaging. Although many patients who present with localized disease are cured with definitive surgery, some patients develop ...
Taking Akt-ion Against Prostate Cancer?
Inhibition of the androgen receptor pathway (AR) with novel hormonal therapies such as abiraterone acetate has greatly improved outcomes for patients with metastatic castration-resistant prostate cancer in recent years. However, through numerous mechanisms, tumors ultimately develop resistance...
Expert Point of View: Paul Wheatley-Price, MRCP
During an International Association for the Study of Lung Cancer (IASLC) press briefing, Paul Wheatley-Price, MRCP, commented as the patient advocate on the panel. Dr. Wheatley-Price is Associate Professor of Medicine at the University of Ottawa, lung cancer disease site lead at Ottawa Hospital...
Pembrolizumab Plus Chemotherapy With or Without Bevacizumab in First-Line Treatment of Advanced Cervical Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 13, 2021, pembrolizumab in combination with...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in acute myeloid leukemia (AML), as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic...
Friends of Cancer Research Releases White Paper on Optimizing Dosing in Oncology Drug Development
During its virtual Annual Meeting 2021 held on November 9 and 10, Friends of Cancer Research (Friends) urged all stakeholders in the cancer community to work together to optimize dosing in oncology drug development to maximize benefit for patients and reduce treatment toxicity, and to abandon the...
Study Finds Unique Genomic and Molecular Features in Young Adult Patients With Cancer
Young adults diagnosed with cancer may require different treatments than those received by older patients, according to a study that systematically compared the genomes of 14 different types of cancers affecting both younger and older adults. The results, published by Lee et al in Cell Reports,...
From Cancer Survivor to Citizen Astronaut
When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...
Expert Point of View: Sophia C. Kamran, MD
Sophia C. Kamran, MD, Assistant Professor of Radiation Oncology at Massachusetts General Hospital, commented on the NRG Oncology GU003 study at a press conference where this abstract was discussed. Dr. Kamran was not involved in this trial. “This is a potentially practice-changing study in an area ...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in AML have led to novel therapies that can target some of them, as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies, Alice S. Mims MD, presented updates in...
2021 State of Lung Cancer Report Finds Survival Has Increased but Remains Significantly Lower for People of Color
The new 2021 State of Lung Cancer report reveals that the 5-year survival rate for lung cancer increased from 14.5% nationally to 23.7%, yet it remains significantly lower among communities of color. The American Lung Association’s fourth annual report also highlights how the toll of lung cancer...
Model May Help Identify Subtypes of Multiple Myeloma
Researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for subtypes of multiple myeloma. They also identified potential targeted treatments based on the findings, which were reported by...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition of a fourth drug to induction treatment regimens and new drug classes are improving treatment for...
Digital Symptom Monitoring System May Improve Patients’ Symptom Control and Physical Function During Cancer Therapy
A digital symptom monitoring system in which patients undergoing cancer treatment could report symptoms through weekly at-home surveys resulted in better symptom control and physical function, as well as improved communication with their medical team, according to results from a study by Basch et...
Study Reveals Genomic Differences Between 14 Tumor Types in Younger vs Older Adults
The results of a study published by Lee et al in Cell Reports suggest that several genetic hallmarks may play key roles in identifying precise treatment options for young adult patients with cancer. The investigators, who systematically compared the genomes of 14 different types of cancers that...
Expert Point of View: Sophia C. Kamran, MD
Sophia C. Kamran, MD, a radiation oncologist at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, who was not involved in the RTOG 0815 study, commented: “The results of RTOG 0815 demonstrate that in the setting of contemporary dose-escalated...
CheckMate 214: Longer Treatment-Free Survival With Immunotherapy vs Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
Patients with advanced renal cell carcinoma receiving first-line therapy with a checkpoint inhibitor combination of nivolumab plus ipilimumab experienced over twice as long treatment-free survival without toxicity compared with patients receiving the targeted therapy sunitinib, according to data...
Researchers Identify Key Link Between Stress and Cancer
Stress can have a significant negative effect on health, but our understanding of how stress impacts the development and progression of cancer is just beginning. A team from Roswell Park Comprehensive Cancer Center has identified an important mechanism by which chronic stress weakens immunity and...
ASCO Quality Improvement Programs Helped to Enhance the Delivery of Cancer Care in Medically Underserved Communities, Article Reports
Oncology practices that participated in a quality improvement project that included ASCO’s Quality Oncology Practice Initiative (QOPI®) and ASCO Quality Training Program (QTP) were able to make improvements in the care provided to underserved populations in their communities, according to a recent...
David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80
David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...
Expert Point of View: Michaela A. Dinan, PhD
Invited discussant of the study on medication nonadherence, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, in Connecticut, noted that the CAHPS survey data provide...
Medication Nonadherence Among Cancer Survivors: Are Indirect Health-Care Costs to Blame?
Approximately 1 in 10 long-term survivors of cancer fails to take medications as prescribed due to financial hardship, according to research presented at the 2021 ASCO Quality Care Symposium.1 However, indirect health-care costs—not drug copays—may be responsible, the study investigators ...
WHO Director-General Grants Posthumous Award to Henrietta Lacks
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, MD, honored the late Henrietta Lacks with a WHO Director-General’s award, recognizing her world-changing legacy. Ms. Lacks, a Black American woman, died of cervical cancer 70 years ago, on October 4, 1951. While she...
Susan G. Komen Announces $1.5 Million in Grants for Metastatic Breast Cancer Research
Susan G. Komen, the world’s leading breast cancer organization, recently announced the award of $1.5 million for three new research projects that examine unique areas focused on metastatic breast cancer. The grants are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research...
Cancer Researcher and Drug Developer, Joseph R. Bertino, MD, Dies at 91
Over the arc of his notable career, Joseph R. Bertino, MD, garnered many honors for his scientific contributions leading to curative treatments for leukemia and lymphoma, such as ASCO’s David A. Karnofsky Award. Yet his legacy was perhaps most prominently punctuated by the multitude of patients...
Early Experiences in the United States Helped Shape an International Oncology Career for Aleix Prat, MD, PhD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Aleix Prat, MD, PhD, Head of the Medical Oncology Department, Hospital Clinic of Barcelona. Dr. Prat, a breast cancer researcher, is currently working to identify strategies to tailor treatment for...
Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases
Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for...
Expert Point of View: Benjamin Besse, MD
Invited discussant Benjamin Besse, MD, of Gustave Roussy Cancer Center, Villejuif, France, was generally positive about the findings of Impower010 but said that longer-term follow-up of overall survival will be very important. “IMpower010 is the first adjuvant study establishing an immune...
Optimizing Adjuvant Therapy for Women With Estrogen Receptor–Positive, Node-Positive Breast Cancer
“Nodal status remains the single most important prognostic marker in outcomes for women with estrogen receptor–positive, HER2-negative breast cancer. For that reason, it makes sense to think about optimizing adjuvant therapy, including endocrine treatments, chemotherapy, and targeted therapy,”...
Racial Disparities in Use of Prostate MRI After Detection of Elevated PSA Levels
In a study published by Abashidze et al in JAMA Network Open, the investigators found that Black men were at least 23.6% less likely than White men to undergo magnetic resonance imaging (MRI) following an elevated prostate-specific antigen (PSA) test result. They also found that Hispanic and Asian...
Early Warning System Model May Help to Predict Deterioration of Hospitalized Patients With Cancer
About 9% of patients with cancer experience complications while hospitalized that lead to a deterioration in their condition, a transfer to the intensive care unit, or death. A multidisciplinary team of researchers at Washington University in St. Louis is developing a machine learning–based early...
Risks and Benefits Associated With Gastrostomy Tubes for Patients With Cancer
In a study published by Gauvin et al in JNCCN–Journal of the National Comprehensive Cancer Network, researchers examined over 200 patients with gastrostomy tubes and highlighted the need for a multidisciplinary approach to palliative care decision-making for patients with cancer. A gastrostomy tube ...
ESMO Women for Oncology Studies Examine Female Leadership in Oncology Over Time
Results of the European Society for Medical Oncology’s (ESMO) Women for Oncology monitoring and authorship studies were recently published by Berghoff et al in ESMO Open. They revealed that women continue to be underrepresented in leadership positions despite making up an increasing proportion of...
Expert Point of View: Michaela A. Dinan, PhD
The invited discussant of the study on out-of-pocket costs of cancer care, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, Connecticut, underscored the study’s key...
Areej El-Jawahri, MD, on the Significance of Patient-Reported Outcomes in Gastrointestinal Cancers
The invited discussant of this study on patient-reported outcomes, Areej El-Jawahri, MD, Associate Director of Cancer Outcomes Research and Education Program and Director of Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital, said these findings underscore the importance...
Patient-Reported Outcomes in Gastrointestinal Cancers: Predicting Treatment Response and Survival Outcomes
According to data presented during the 2021 ASCO Quality Care Symposium,1 1-month changes in patient-reported outcomes may predict treatment response and survival outcomes in patients with advanced gastrointestinal cancers. The results of a prospective study of 159 patients with metastatic...
Effect of Social Determinants of Health on Receipt of Survivorship Care Plans
Survivorship care plans are an important tool to help cancer survivors transition from active treatment to follow-up care, but a study published by Timsina et al in Supportive Care in Cancer has found that a number of vulnerable groups have a lower likelihood of receiving such plans. Cancer...
